{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:45:41Z","timestamp":1789728341955,"version":"4.0.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Ornithine transcarbamylase deficiency (OTCD) is the most common disorder of the urea cycle and is caused by a mutation of the <jats:italic>OTC<\/jats:italic> gene, located on chromosome X. Its prevalence is estimated at 1 in 80,000 to 56,500 births, but this X-chromosomal inheritance results in males being more affected than females. In neonates affected with this disorder, hyperammonemia after birth can lead to neurological and liver damage that can be fatal. We present a child with a prenatal diagnosis based on an older sibling with the same pathology, which led us to adopt an intensive treatment since the delivery. He was admitted in a neonatal unit and treatment with protein restriction, 10% glucose saline serum and glycerol phenylbutyrate was initiated. To date, after 3.5\u2009years of follow up, growth and neurological development have been adequate, biochemical control has been appropriate except for a simple and mild decompensation during the course of a gastroenteritis. This case emphasises the importance of early diagnosis and treatment to avoid potential complications.<\/jats:p>","DOI":"10.3389\/fnut.2024.1416466","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:42:35Z","timestamp":1727671355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Perinatal management and follow-up in a child with a prenatal diagnosis of OTC deficiency: a case report"],"prefix":"10.3389","volume":"11","author":[{"given":"\u00c1lvaro","family":"Mart\u00edn-Rivada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Murray Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mart\u00edn-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref1","article-title":"Ornithine transcarbamylase deficiency","volume-title":"GeneReviews","author":"Lichter-Konecki","year":"2013"},{"key":"ref2","article-title":"Defectos del ciclo de la urea","volume-title":"Diagn\u00f3stico y Tratamiento de las Enfermedades Metab\u00f3licas Hereditarias","author":"H\u00e4berle","year":"2022"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ymgme.2013.07.008","article-title":"The incidence of urea cycle disorders","volume":"110","author":"Summar","year":"2013","journal-title":"Mol Genet Metab"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1055\/s-0030-1254240","article-title":"Management of ornithine transcarbamylase deficiency in pregnancy","volume":"27","author":"Mendez-Figueroa","year":"2010","journal-title":"Am J Perinatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ymgme.2018.01.004","article-title":"Prenatal treatment of ornithine transcarbamylase deficiency","volume":"123","author":"Wilnai","year":"2018","journal-title":"Mol Genet Metab"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/nu16010013","article-title":"Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice","volume":"16","author":"Burlina","year":"2023","journal-title":"Nutrients"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"112798","DOI":"10.1016\/j.jpba.2019.112798","article-title":"Quantification of urinary derivatives of phenylbutyric and benzoic acids by LC-MS\/MS as treatment compliance biomarkers in urea cycle disorders","volume":"176","author":"Andrade","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.ymgme.2010.02.007","article-title":"Nitrogen sparing therapy revisited 2009","volume":"100","author":"Enns","year":"2010","journal-title":"Mol Genet Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jpeds.2012.06.065","article-title":"Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ","volume":"162","author":"Mew","year":"2013","journal-title":"J Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jimd.12100","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision","volume":"42","author":"H\u00e4berle","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"11948","DOI":"10.1038\/s41598-020-67496-3","article-title":"Long-term effects of medical management on growth and weight in individuals with urea cycle disorders","volume":"10","author":"Posset","year":"2020","journal-title":"Sci Rep"},{"key":"ref12","article-title":"WHO child growth standards. Length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age","year":""},{"key":"ref13","article-title":"Protocolo de diagn\u00f3stico y tratamiento de los trastornos del ciclo de la urea","volume-title":"Protocolos de diagn\u00f3stico y tratamiento de los Errores Cong\u00e9nitos del Metabolismo","author":"Pintos Morell","year":"2018"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3390\/children10081368","article-title":"Diagnostic and management issues in patients with late-onset ornithine transcarbamylase deficiency","volume":"10","author":"Ibrahim","year":"2023","journal-title":"Children"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/ajmg.a.61329","article-title":"Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: a systematic review","volume":"179","author":"Torkzaban","year":"2019","journal-title":"Am J Med Genet A"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.20960\/nh.04867","article-title":"Two pregnancies of an ornithine carbamoyltransferase deficiency disease carrier and review of the literature","volume":"41","author":"Arhip","year":"2024","journal-title":"Nutr Hosp"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e00390","DOI":"10.1016\/j.crwh.2022.e00390","article-title":"Ornithine transcarbamylase deficiency and pregnancy: a case series and review of recommendations","volume":"34","author":"Pinho","year":"2022","journal-title":"Case Rep Womens Health"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100894","DOI":"10.1016\/j.ymgmr.2022.100894","article-title":"Considerations for prenatal and postpartum management of a female patient with ornithine transcarbamylase deficiency","volume":"33","author":"Feigenbaum","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"ref19","article-title":"Management of a baby at risk of a urea cycle disorder at birth","year":"2024"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/jimd.12404","article-title":"OTC deficiency in females: phenotype-genotype correlation based on a 130-family cohort","volume":"44","author":"Gobin-Limballe","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/1096-8628(20000814)93","article-title":"Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype","volume":"93","author":"McCullough","year":"2000","journal-title":"Am J Med Genet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-015-0266-1","article-title":"Long-term outcomes in ornithine transcarbamylase deficiency: a series of 90 patients","volume":"10","author":"Brassier","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.3390\/jcm11175045","article-title":"Switching to glycerol phenylbutyrate in 48 patients with urea cycle disorders: clinical experience in Spain","volume":"11","author":"Mart\u00edn-Hern\u00e1ndez","year":"2022","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2020.12.002","article-title":"Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders","volume":"132","author":"Longo","year":"2021","journal-title":"Mol Genet Metab"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1067\/mpd.2001.111837","article-title":"Long-term management of patients with urea cycle disorders","volume":"138","author":"Berry","year":"2001","journal-title":"J Pediatr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ymgme.2012.08.006","article-title":"Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders","volume":"107","author":"Mokhtarani","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10545-016-9938-9","article-title":"Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders","volume":"39","author":"Posset","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jimd.12209","article-title":"Choosing between medical management and liver transplant in urea cycle disorders: a conceptual framework for parental treatment decision-making in rare disease","volume":"43","author":"Gerstein","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/lt.23765","article-title":"Pediatric liver transplantation for urea cycle disorders and organic acidemias: united network for organ sharing data for 2002\u20132012","volume":"20","author":"Perito","year":"2014","journal-title":"Liver Transpl"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/jimd.12609","article-title":"Gene therapy for urea cycle defects: an update from historical perspectives to future prospects","volume":"47","author":"Duff","year":"2024","journal-title":"J Inherit Metab Dis"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1416466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:42:37Z","timestamp":1727671357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1416466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":30,"alternative-id":["10.3389\/fnut.2024.1416466"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2024.1416466","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1416466"}}